九游会·J9-官方网站|真人游戏第一品牌
Other Affiliated Sites
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Financial Reports
Announcements
2025.08.29
j9九游会:半年度非经营性资金占用及其他关联资金往来情况汇总表
2025.08.29
j9九游会:2025年半年度财务报告
2025.08.29
j9九游会:2025年半年度报告摘要
2025.08.29
j9九游会:2025年半年度报告
2025.07.18
j9九游会:关于H1710完成I期临床试验首例受试者入组及首次给药的公告
2025.06.27
j9九游会:2024年年度权益分派实施公告
2025.06.17
j9九游会:关于依诺肝素钠注射液获得EMA新增生产商批准的公告
2025.05.23
j9九游会:2024年年度股东大会决议公告
2025.04.24
j9九游会:监事会决议公告
2025.04.24
j9九游会:关于依诺肝素钠注射液获得南非药品注册批件的公告
第一页
上一页
1
2
3
4
5
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.